Genetic screening in Parkinson*s disease patients to identify GBA1 mutation carriers for future clinical trials.

Genetic screening in Parkinson*s disease patients to identify GBA1 mutation carriers for future clinical trials. - Genetic screening for GBA1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56348

Enrollment

1000

Registered

2023-11-02

Start date

2023-11-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age 40-80 years of age at screening (inclusive). 2. All participants must understand and provide written informed consent prior to any study-specific procedures 3. Able to speak, read, and understand study procedures in Dutch sufficiently to allow completion of all study assessments. 4. Patient-reported clinical diagnosis of Parkinson*s disease by a neurologist within the last 10 years.

Exclusion criteria

Exclusion criteria: 1. Known non-GBA-1 mutation for Parkinson*s disease

Design outcomes

Primary

Measure	Time frame
Sequence of the full GBA1 gene, classified as wildtype or mutated, with specifications of the mutation	—

Countries

Netherlands

Outcome results